MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Medical Trial of MYMD-1 as a Treatment for Delaying Aging as well as Extending Healthy And Balanced Life Expectancy

MyMD Pharmaceuticals, Inc. MYMD stock price (” MyMD” or “the Firm”), a medical stage pharmaceutical business devoted to extending healthy lifespan, today announced that the initial individual has been signed up in the Firm’s Stage 2 scientific trial of lead prospect MYMD-1, an oral immune regulatory authority drug, as a therapy for delaying aging and also expanding healthy and balanced life-span.

The main endpoint for the Stage 2 double-blind, placebo-controlled clinical test is to achieve a decrease in the flowing levels of (TNF-α), tumor death aspect receptor I (TNFRI) as well as IL-6. TNF-α and also IL-6 are the healthy proteins in the body that cause inflammation and also assist trigger the process of aging. The second steps of the test will certainly be the safety, tolerability, and pharmacokinetics in this population of patients.

” In a Stage 1 professional trial of MYMD-1, we demonstrated the medicine’s statistically significant efficacy in decreasing degrees of TNF-α, a principal in causing pathological aging, in the blood. The FDA has accepted TNF-α decrease as the main endpoint for our Stage 2 study, which we believe positions us well for an effective Stage 2 end result,” claimed Chris Chapman, M.D., President, Supervisor as well as Principal Medical Police Officer of MyMD. “The initiation of patient enrollment in this research advances our goal to slow down the aging process, prevent loss of muscle tissue in aging, limit frailty, and also prolong healthy and balanced lifespan.”

MyMD has specified that there are no FDA-approved medications for treating aging disorders and expanding healthy lifespan people, a market expected to be at the very least $600 billion by 20251 according to a major investment financial institution. TNF-α blockers are the most proposed medicines by earnings, a worldwide market of roughly $40 billion each year,2 and, according to Nature Aging journal,3 a slowdown in maturing that would boost life span by one year deserves $38 trillion and by one decade deserves $367 trillion.

In addition to aging, MYMD-1’s distinct action in controling the body immune system and also dealing with persistent swelling is being developed for the treatment of autoimmune condition, consisting of rheumatoid arthritis (RA), numerous sclerosis (MS), diabetic issues, and also inflammatory bowel illness.

” We mean to begin writing procedures for a Stage 2 pilot research study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The rising frequency of rheumatoid joint inflammation and various other autoimmune as well as inflammatory illness are driving demand for TNF preventions like MYMD-1, and our company believe our orally provided drug with very reduced toxicity would be turbulent to the $60 billion market for RA if accepted by the FDA for this indicator.”

Rheumatoid arthritis impacts around 40 million people globally.4.

Concerning MYMD-1.

Initially developed for autoimmune illness, MYMD-1’s primary purpose is to slow down the aging procedure, avoid sarcopenia and also frailty, and also extend healthy and balanced life expectancy. Because it can cross the blood-brain barrier and get to the main nerves (CNS), MYMD-1 is additionally placed to be a feasible therapy for brain-related conditions. Its system of action and efficacy in conditions including several sclerosis (MS) and also thyroiditis have actually been researched through partnerships with numerous academic organizations. MYMD-1 is also revealing pledge in pre-clinical studies as a prospective therapy for post- COVID-19 difficulties and as an anti-fibrotic and anti-proliferation therapeutic.

MYMD-1 has actually shown performance in pre-clinical studies in managing the body immune system by doing as a discerning inhibitor of tumor death factor-alpha (TNF-α), a driver of chronic swelling. Unlike various other treatments, MYMD-1 has been received these pre-clinical research studies to selectively obstruct TNF-α when it becomes overactivated in autoimmune illness and also cytokine tornados, but not obstruct it from doing its regular task of being a very first responder to any kind of regular kind of moderate infection. MYMD-1’s ease of dental dosing is one more differentiator compared to currently offered TNF-α blockers, every one of which call for shipment by shot or mixture. No authorized TNF inhibitor has ever before been dosed orally. In addition, the medicine is not immunosuppressive and also has not been shown to cause the significant side effects usual with conventional therapies that treat inflammation.

About MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical phase pharmaceutical business dedicated to expanding healthy and balanced life expectancy, is focused on establishing two unique restorative platforms that deal with the causes of disease instead of only resolving the symptoms. MYMD-1 is a medicine system based upon a scientific stage small molecule that manages the body immune system to manage TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to delay aging, increase long life, as well as treat autoimmune illness and COVID-19- associated clinical depression. The Company’s 2nd medication platform, Supera-CBD, is being created to treat chronic pain, addiction and also epilepsy. Supera-CBD is a novel artificial derivative of cannabidiol (CBD) as well as is being established to attend to as well as surpass the swiftly expanding CBD market, that includes both FDA accepted drugs and also CBD items not presently managed as medicines. For more details, check out www.mymd.com.